Zanubrutinib Pill

Phase 2

BeiGene, Ltd. (BGNE)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Mar '27

BGNEPhase 2

Zanubrutinib Pill Phase 2 Est. Readout

Zanubrutinib Pill• Leukemia, Lymphocytic, Chronic, B-Cell50

Mar 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Leukemia, Lymphocytic, Chronic, B-Cell

View Full Landscape

Drug Information

Target Indication

Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trial

NCT05650723

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BGNE

BeiGene, Ltd.

Biotechnology•North America•NASDAQ

Related Pipeline

CisplatinPhase 3

Esophageal Squamous Cell Carcinoma (ESCC)

VenetoclaxPhase 3

Chronic Lymphocytic Leukemia

OxaliplatinPhase 3

Gastric, or Gastroesophageal Junction Adenocarcinoma

Gemcitabine HydrochloridePhase 3

Urothelial Carcinoma

CarboplatinPhase 3

Non-Small Cell Lung Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts